• Vi på PULS önskar en trevlig sommar!
  • Adenovir Pharma förstärker styrelsen med två ledamöter: Karin Wingstrand och Mats Lidgard
  • Glactone Pharma innovators publish new study in the scientific journal European Urology

Sweden's leading private life science incubator

PULS turns life science projects into attractive business opportunities for the life science industry. Each project is based on a well-defined medical need. PULS secures long-term financing and world-class scientific and industrial expertise through joint ownership with innovators. Our track record validates all aspects of our business model – a model that serves both innovators and investors well. Try us!

News from PULS

7 July, 2015

Glactone Pharma innovators publish new study showing that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer

Members of Glactone Pharma’s innovator group have published an article in the highly rated scientific journal European Urology: “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology, impact factor 13.938 (Eur Urol. 2015, doi:10.1016/j.eururo.2015.06.016).

29 June, 2015

Adenovir får anslag från VINNOVA för andra generationens läkemedel mot smittsam ögoninfektion

Adenovir utvecklar läkemedel mot den smittsamma ögonsjukdomen EKC (epidemiskt keratokonjunktivit) varav ett nu testas i fas II. EKC orsakas av adenovirus och drabbar årligen ett mycket stort antal människor och kan ge upphov till synnedsättning. Sjukdomen saknar idag effektiv behandling. VINNOVA har tilldelat Adenovir SA Development AB ett anslag om 500.000 kr för farmaceutisk utveckling […]

Find out more
Innovators
Do you have an idea?
Partners
Do you have the knowledge?
Investors
Do you have the experience?

© 2012-2015 P.U.L.S. AB | Kullagatan 8, 252 20 Helsingborg, Sweden | All rights reserved.